There are concerns about kid's growth so its is important to do these trials but big picture Novo is in trouble.

For thing Zepbound is the better drug and Lilly has kept up production. Lilly's new small-molecule drug

https://en.wikipedia.org/wiki/Orforglipron

has the potential of being cheaper to produce than peptide engineered products, in fact a better business because an incumbent manufacturer working at scale is likely to have a better cost structure than competitors to make a small molecule drug once it goes off patent. Still Orforlgipron is not that impressive in results causing a loss of just 8% of body weight which is not as good as the Wegovy Pill which manages 16% despite the difficulty of getting a peptide into people by the oral route.